Impact of edaravone on serum CXC chemokine ligand-13 levels and perioperative neurocognitive disorders in elderly patients with hip replacement.
10.1097/CM9.0000000000001492
- Author:
Hai-Hui XIE
1
;
Hong-Yan MA
2
;
Shu ZHANG
1
;
Jian-Wen LI
3
;
Qi HAN
1
;
Hui-Qun CHEN
1
;
Bo-Qin SU
1
;
Jian-Ping ZHOU
1
Author Information
1. Department of Anesthesiology, Affiliated Dongguan People's Hospital of Southern Medical University, Dongguan, Guangdong 523018, China.
2. Department of Nephrology, First Hospital of Jilin University, Changchun, Jilin 130021, China.
3. Department of Orthopaedics, Affiliated Dongguan People's Hospital of Southern Medical University, Dongguan, Guangdong 523018, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Aged;
Arthroplasty, Replacement, Hip/adverse effects*;
Chemokines, CXC/drug effects*;
Delirium;
Double-Blind Method;
Edaravone;
Humans;
Ligands;
Postoperative Complications
- From:
Chinese Medical Journal
2021;134(13):1610-1615
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Perioperative neurocognitive disorders (PND) are a series of severe complications in the perioperative and anesthetic periods with a decline in memory, execution ability, and information processing speed as the primary clinical manifestation. This study aimed to evaluate the impact of edaravone (EDA) on PND and peripheral blood C-X-C motif chemokine ligand 13 (CXCL13) levels in elderly patients with hip replacement.
METHODS:A total of 160 elderly patients undergoing hip arthroplasty in Affiliated Dongguan People's Hospital of Southern Medical University (from March 2016 to March 2018) were randomly and double-blindly categorized into an EDA group and a control group (CON). Group EDA was administered intravenously EDA 30 min before surgery, and group CON was administered intravenously saline. The cognitive function of the two groups was evaluated 1-day before the operation and at 1 and 12 months after surgery, and the incidence of post-operative delirium was tested on days 1, 3, and 7 after surgery using the Chinese version of the confusion assessment method. Serum CXCL13 and interleukin (IL)-6 concentrations were measured before anesthesia, during surgery (30 min after skin incision), and on days 1, 3, and 7 after surgery. The continuous variables in accordance with normal distribution were tested using the Student's t test, the continuous variables without normal distribution using the Mann-Whitney U test, and categorical variables by the χ2 test or Fisher exact test.
RESULTS:The incidence of post-operative delirium within 7 days after surgery was significantly higher in group CON than that in group EDA (31.3% vs. 15.0%, t = -5.6, P < 0.001). The modified telephone interview for cognitive status and activities of daily life scores were significantly higher in the group EDA than those in the group CON at 1 month (39.63 ± 4.35 vs. 33.63 ± 5.81, t = -2.13, P < 0.05 and 74.3 ± 12.6 vs. 61.2 ± 13.1, t = -1.69, P < 0.05) and 12 months (40.13 ± 5.93 vs. 34.13 ± 5.36, t = -3.37, P < 0.05 and 79.6 ± 11.7 vs. 65.6 ± 16.6, t = -2.08, P < 0.05) after surgery; and the incidence of neurocognitive dysfunction was significantly lower in the group EDA than that in the group CON (P < 0.05). Serum CXCL13 and IL-6 concentrations were significantly lower in the group EDA than those in the group CON during and after surgery (P < 0.05).
CONCLUSION:EDA can significantly reduce the serum concentrations of CXCL13 and IL-6 and improve the PND of patients.
